Arbutus Biopharma Corp Payments to Acquire Restricted Investments
Arbutus Biopharma Corp (ABUS) reported Payments to Acquire Restricted Investments of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-16.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireRestrictedInvestments · last filed 2018-03-16
- Arbutus Biopharma Corp payments to acquire restricted investments for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- Arbutus Biopharma Corp payments to acquire restricted investments for fiscal 2016 was $12.60M.
- Arbutus Biopharma Corp payments to acquire restricted investments for fiscal 2015 was $0.00.
- Arbutus Biopharma Corp payments to acquire restricted investments for fiscal 2014 was $0.00.
| Period end | Payments to Acquire Restricted Investments 12 month |
|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-03-16 |
| 2016-12-31 | $12.60M 10-K · filed 2018-03-16 |
| 2015-12-31 | $0.00 10-K · filed 2018-03-16 |
| 2014-12-31 | $0.00 10-K · filed 2017-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |